Vanguard Global Advisers
BCRX icon

Vanguard Global Advisers’s BioCryst Pharmaceuticals BCRX Stock Holding History

Vanguard Global Advisers’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$925K Sell
92,513
-5,738
-6% -$51.9K ﹤0.01% 1795
2026
Q1 		$935K Buy
+98,251
New +$763K ﹤0.01% 1690

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Vanguard Global Advisers's BCRX Position: Q2 2026 in Review

Vanguard Global Advisers reduced its BioCryst Pharmaceuticals (BCRX) stake by 5.8% in Q2 2026, selling an estimated $51.9K and leaving 92,513 shares worth $925K. The position accounts for ﹤0.01% of the portfolio, ranked #1795.

Vanguard Global Advisers first reported a position in BCRX in Q1 2026 and has held it in 2 quarters since. The position peaked at $935K in Q1 2026. 315 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Vanguard Global Advisers held 92,513 shares of BioCryst Pharmaceuticals worth $925K as of Q2 2026.
  • Vanguard Global Advisers sold 5,738 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $51.9K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1795 holding.
  • Vanguard Global Advisers first reported a position in BioCryst Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's BioCryst Pharmaceuticals position peaked at $935K in Q1 2026.
  • 315 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.